alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 6,076–6,100 of 27,380 studies, newest first · page 244 of 1096.

October 2024 25

  1. 2024-10-30

    Plasma Neurodegenerative Biomarkers in Cognitively Preserved Nonagenarians

    ✓ Peer-reviewed Biomarkers Aging and disease

    Key finding: In this study we analyzed plasma Alzheimer's disease (AD) core biomarkers, neurofilament light chain (NfL), and glial fibrillary acid protein (GFAP) using the Single Molecule Array (SIMOA) platform in 75 cognitively preserved nonagenarians, and compared with baseline samples of 153 volunteers who were cognitively unimpaired (CU) during six years (classified in ≤ 70, and 71 to 85 years of age), and with 108 AD patients. +4 more findings

    Full summary, score breakdown and related studies → Original source

  2. 2024-10-29

    Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia

    ✓ Peer-reviewed Costs and economics Journal of health economics and outcomes research

    Key finding: Of 2 684 704 Fee-for-Service patients with Alzheimer dementia, 769 141 met all inclusion criteria; among these, 281 042 (36.5%) had agitation. +4 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2024-10-29

    Anti-amyloid treatments for Alzheimer's disease: A study on physicians' perspectives

    ✓ Peer-reviewed Treatments Journal of Alzheimer's disease : JAD

    Key finding: A survey of Israeli specialists found that 84% were familiar with new ATT, but 60% raised doubts about their ability to significantly impact disease progression.

    Full summary, score breakdown and related studies → Original source

  4. 2024-10-29

    Lecanemab: Appropriate Use Recommendations by Korean Dementia Association

    ✓ Peer-reviewed Treatments Dementia and neurocognitive disorders

    Key finding: Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2024-10-28

    Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness

    ✓ Peer-reviewed Treatments Scientific reports

    Key finding: Despite most monoclonal antibodies against Aβ in Alzheimer's failed to demonstrate efficacy, the newest antibodies showed statistically significant clinical effects. +2 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2024-10-27

    A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic

    ⚠ Preprint — not yet peer-reviewed Tau biomarkers medRxiv

    Key finding: Blood-based biomarkers for Alzheimer’s disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. +3 more findings

    Scored 35 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

    Full summary, score breakdown and related studies → Original source

  7. 2024-10-26

    Neurodegenerative Disorders and the Gut-Microbiome-Brain Axis: A Literature Review

    ✓ Peer-reviewed Disease mechanisms Cureus

    Key finding: Neurodegenerative diseases are severe, age-related conditions with complex etiologies that result in significant morbidity and mortality. +3 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2024-10-25

    Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective

    ✓ Peer-reviewed Drug development Brain, behavior, & immunity - health

    Key finding: Doxycycline, a broad-spectrum antibiotic belonging to the tetracycline class, has demonstrated potential activity against neurodegenerative diseases like Alzheimer's and Parkinson's.

    Full summary, score breakdown and related studies → Original source

  9. 2024-10-25

    Neurovascular unit, neuroinflammation and neurodegeneration markers in brain disorders

    ✓ Peer-reviewed Biomarkers Frontiers in cellular neuroscience

    Key finding: In this review, we discuss markers of neuroinflammation, and neurodegeneration associated with acute and chronic brain disorders, especially those associated with neurovascular pathologies.

    Full summary, score breakdown and related studies → Original source

  10. 2024-10-25

    Neuronal plasma biomarkers in acute ischemic stroke

    ✓ Peer-reviewed Biomarkers Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

    Key finding: Linear regression confirmed BD-tau to be the strongest variable associated with stroke diameter, pointing to the potential clinical value of plasma BD-tau in outcome prediction after AIS.

    Full summary, score breakdown and related studies → Original source

  11. 2024-10-25

    Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer's disease: a pilot study

    ✓ Peer-reviewed Biomarkers Scientific reports

    Key finding: Nanoparticle tracking analysis revealed a high variance in EV distribution. +2 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2024-10-25

    Apolipoprotein E Induces Lipid Accumulation Through Dgat2 That Is Prevented with Time-Restricted Feeding in Drosophila

    ✓ Peer-reviewed Risk factors Genes

    Key finding: We report that pan-neuronal expression of each ApoE allele induces lipid accumulation specifically in the brain, but not in the muscle. +4 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2024-10-24

    [18F]PI-2620 Tau PET signal across the aging and Alzheimer's disease clinical spectrum

    ✓ Peer-reviewed Brain scans and imaging Imaging neuroscience (Cambridge, Mass.)

    Key finding: Using real and interpolated 45-75 min data, we next examined [18F]PI-2620 signal in Braak regions of interest and an off-target binding region (putamen) in Aβ- and Aβ+ CU, Aβ+ MCI, and Aβ+ AD dementia (n = 115) and showed that SUVRs in all Braak regions increased with greater disease severity. +1 more finding

    Full summary, score breakdown and related studies → Original source

  14. 2024-10-24

    Plasma phosphorylated tau181 outperforms [18F] fluorodeoxyglucose positron emission tomography in the identification of early Alzheimer disease

    ✓ Peer-reviewed Tau biomarkers European journal of neurology

    Key finding: This study was undertaken to compare the performance of plasma p-tau181 with that of [ 18 F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in the identification of early biological Alzheimer disease (AD). +3 more findings

    Full summary, score breakdown and related studies → Original source

  15. 2024-10-24

    Intravenous chaperone treatment of late-stage Alzheimer´s disease (AD) mouse model affects amyloid plaque load, reactive gliosis and AD-related genes

    ✓ Peer-reviewed Biomarkers Translational psychiatry

    Key finding: Sequencing of RNA from cortical microglia cells showed that BRICHOS treatment normalized the expression of identified plaque-induced genes in mice and humans, including clusterin and GFAP. +1 more finding

    Full summary, score breakdown and related studies → Original source

  16. 2024-10-23

    Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration

    ✓ Peer-reviewed Drug development Cellular and molecular neurobiology

    Key finding: Our results showed that metformin administration to the TMT group mitigated learning and memory impairment in Barnes maze, novel object recognition (NOR) task, and Y maze, attenuated hippocampal oxidative, inflammatory, and cell death/pyroptotic factors, and also reversed neurodegeneration-related proteins such as presenilin 1 and p-Tau. +1 more finding

    Full summary, score breakdown and related studies → Original source

  17. 2024-10-23

    The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy

    ✓ Peer-reviewed Treatments EMBO reports

    Key finding: The recent rejection of lecanemab by the European Medicines Agency despite its approval in other countries highlights the debate among researchers and regulatory bodies about the efficacy, safety, and underlying scientific basis of drugs to treat Alzheimer’s disease. [Image: see text]

    Full summary, score breakdown and related studies → Original source

  18. 2024-10-23

    ATN blood biomarkers are related to digital cognitive assessment in type 1 diabetes

    ✓ Peer-reviewed Cognitive tests and assessment Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: Higher concentrations of pTau181 and GFAP were associated with slower responses on working memory tasks (pTau181: β = 0.261; p = 0.007; GFAP: β = 0.175, p = 0.036), and higher β-amyloid 42/40 ratio was associated with better vocabulary (β = 0.260, p = 0.009). +3 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2024-10-23

    Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease

    ✓ Peer-reviewed TREM2 and immune genetics Alzheimer's research & therapy

    Key finding: Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. +3 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2024-10-23

    Blood-derived mitochondrial DNA copy number is associated with Alzheimer disease, Alzheimer-related biomarkers and serum metabolites

    ✓ Peer-reviewed Biomarkers Alzheimer's research & therapy

    Key finding: MR analysis suggested a causal relationship between decreased blood-derived mtDNA-CN and increased risk of AD (OR = 0.68; P = 0.013). +4 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2024-10-22

    Prevalence of Unrecognized Cognitive Impairment in Federally Qualified Health Centers

    ✓ Peer-reviewed Risk factors JAMA Network Open

    Key finding: A total of 844 eligible individuals were consecutively approached, 294 consented to participate, and 204 completed the study (mean [SD] age, 70.0 [5.1] years; 127 women [62.3%]). +4 more findings

    Full summary, score breakdown and related studies → Original source

  22. 2024-10-22

    The Effect of the "Safety in Dementia" Online Tool to Assist Decision Making for Caregivers of Persons With Dementia and Access to Firearms: A Randomized Trial

    ✓ Peer-reviewed Caregiving Annals of Internal Medicine

    Key finding: The online SiD decision aid increased preparation for decision making about firearm access in this sample of ADRD caregivers in the United States. +4 more findings

    Full summary, score breakdown and related studies → Original source

  23. 2024-10-21

    Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease

    ✓ Peer-reviewed Treatments Molecular neurodegeneration

    Key finding: Our study has established a significant link between CAA-Aβ antibody immune complex formation, immune activation and vascular damage leading to smooth muscle cell loss. +4 more findings

    Full summary, score breakdown and related studies → Original source

  24. 2024-10-21

    Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform

    ✓ Peer-reviewed Biomarkers EBioMedicine

    Key finding: Plasma pTau217 had a high correlation with both Aβ Centiloid (r = 0.76) and tau SUVR meta-temporal (r = 0.78). +1 more finding

    Full summary, score breakdown and related studies → Original source

  25. 2024-10-20

    Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study

    ✓ Peer-reviewed Brain tissue and pathology Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: SAA+ individuals had faster cognitive decline than SAA-, notably in mild cognitive impairment, and presented with earlier symptom onset. +4 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →